LFG
ALXN

LifePlan Financial Group’s Alexion Pharmaceuticals ALXN Stock Holding History

LifePlan Financial Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$17K Hold
150
– – 0.01% 361
2020
Q2 		$17K Hold
150
– – 0.01% 367
2020
Q1 		$13K Hold
150
– – 0.01% 376
2019
Q4 		$16K Hold
150
– – 0.01% 376
2019
Q3 		$15K Buy
+150
New +$16.9K 0.01% 383

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LifePlan Financial Group's ALXN Position: Q3 2020 in Review

LifePlan Financial Group held its Alexion Pharmaceuticals (ALXN) position steady in Q3 2020 at 150 shares worth $17K. The position accounts for 0.01% of the portfolio, ranked #361.

LifePlan Financial Group first reported a position in ALXN in Q3 2019 and has held it in 5 quarters since. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • LifePlan Financial Group held 150 shares of Alexion Pharmaceuticals worth $17K as of Q3 2020.
  • LifePlan Financial Group left its Alexion Pharmaceuticals share count unchanged in Q3 2020.
  • Alexion Pharmaceuticals made up 0.01% of LifePlan Financial Group's portfolio in Q3 2020, its #361 holding.
  • LifePlan Financial Group first reported a position in Alexion Pharmaceuticals in Q3 2019 and has held it in 5 quarters since.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on LifePlan Financial Group's 13F filing for Q3 2020, filed 30 Oct 2020.